Sanara Medtech Announced That Is Has Signed An Exclusive License Agreement With Tufts University To Develop And Commercialize Patented Technology Covering 18 Unique Collagen Peptides
Sanara Medtech Announced That Is Has Signed An Exclusive License Agreement With Tufts University To Develop And Commercialize Patented Technology Covering 18 Unique Collagen Peptides
Sanara Medtech宣佈已與塔夫茨大學簽署了獨家許可協議，以開發和商業化涵蓋18種獨特膠原蛋白肽的專利技術
- As part of this agreement, Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC ("SCP"), and has issued 10% of SCP's outstanding units to Tufts.
- SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents pending.
- The agreement includes one U.S. patent, one granted European patent (validated in France, Germany, Great Britain, and Switzerland/Liechtenstein), one Canadian patent pending, and one Patent Cooperation Treaty ("PCT") patent pending.
- SCP will pay royalties to Tufts based on net sales of licensed products and technologies. Royalties will be calculated at a rate of 1.5% or 3%, depending on the type of product or technology developed.
- SCP will pay Tufts a minimum annual royalty of $50,000 on January 1 of the year following the first anniversary of the first commercial sale of the licensed products or technologies. SCP will pay Tufts a $100,000 minimum annual royalty on January 1 of each subsequent year during the royalty term specified in the exclusive license agreement.
- 作爲該協議的一部分，Sanara成立了新的子公司Sanara Collagen Peptides, LLC（“SCP”），並已向塔夫茨發行了SCP剩餘單位的10％。
- SCP擁有基於許可專利和待審專利開發和商業化新產品的專有權利。
- 該協議包括一項美國專利、一項已獲授權的歐洲專利（在法國、德國、英國和瑞士/列支敦士登有效）、一項加拿大正在申請的專利和一項待批准的《專利合作條約》（“PCT”）專利。
- SCP將根據許可產品和技術的淨銷售額向塔夫茨支付特許權使用費。特許權使用費將按1.5％或3％的稅率計算，具體取決於所開發的產品或技術的類型。
- SCP將在授權產品或技術首次商業銷售一週年後的當年1月1日向塔夫茨支付至少5萬美元的年度特許權使用費。在獨家許可協議規定的特許權使用費期限內，SCP將在次年的1月1日向塔夫茨支付最低10萬美元的年度特許權使用費。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。